Invivyd, Inc. (IVVD) Key Metrics

NASDAQ: IVVDValuation, returns, debt and efficiency ratios over 6 years.

IVVD valuation today

Trailing 12 months · as of October 17, 2026
Market cap
$182.3M
Enterprise value
$120.0M
P/E (TTM)
—
Forward P/E
44.6
PEG ratio
—
Price / sales
3.1
Price / book
1.5
10-yr median 1.4
EV / EBITDA
0.8
Dividend yield
—
Beta
0.95

IVVD key metrics, 2020–2025

Fiscal year ended December 31, 2025 · U.S. dollars

IVVD valuation Price multiples at each fiscal year-end price.

Price / sales+284.7%
8.0
2025 · hover or tap a bar for each year
2024: 2.12025: 8.0 (+284.7%)
20202025
Price / book+126.4%
1.8
2025 · hover or tap a bar for each year
2021: 1.42022: 0.5 (−68.3%)2023: 2.4 (+433.0%)2024: 0.8 (−68.0%)2025: 1.8 (+126.4%)
20202025
Free cash flow yield+311.1 pts
−13.7%
2025 · hover or tap a bar for each year
2021: −23.0%2022: −136.5% (−113.5 pts)2023: −40.3% (+96.2 pts)2024: −324.8% (−284.5 pts)2025: −13.7% (+311.1 pts)
20202025

IVVD valuation history

Fiscal year-endToday6-year median

IVVD returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

IVVD debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

IVVD cash returned to shareholders

DividendsBuybacksFree cash flow

IVVD price vs earnings per share

Share price at year-endEPS (right axis)

IVVD key metrics

2020–2025
Invivyd, Inc. key metrics by fiscal year
202520242023202220212020
Valuation
Market capitalization$425.4M$52.5M$431.5M$162.4M$804.3M—
Enterprise value$201.2M−$15.5M$233.1M−$205.9M$212.9M—
Price / sales8.02.1————
Price / book1.80.82.40.51.4—
EV / sales3.8-0.6————
Earnings yield−12.3%−323.5%−46.0%−148.6%−28.2%—
Free cash flow yield−13.7%−324.8%−40.3%−136.5%−23.0%—
Shareholder yield (dividends + buybacks)0.1%0.0%0.0%0.0%0.0%—
Share price at fiscal year-end$2.47$0.44$3.94$1.50$7.26—
Per share
Revenue per share$0.31$0.21$0.00$0.00$0.00$0.00
Earnings per share−$0.30−$1.43−$1.81−$2.23−$2.05−$1.01
Operating cash flow per share−$0.34−$1.44−$1.58−$2.03−$1.67−$0.13
Free cash flow per share−$0.34−$1.44−$1.59−$2.05−$1.67−$0.13
Cash per share$1.32$0.58$1.83$3.44$5.34$1.03
Book value per share$1.40$0.57$1.62$3.29$5.04−$0.59
Tangible book value per share$1.40$0.57$1.62$3.29$5.04−$0.59
Capex per share$0.00$0.00$0.01$0.02$0.00$0.00
Debt per share$0.01$0.01$0.02$0.03——
Shares outstanding172.2M118.6M109.5M108.3M110.8M111.2M
Change in shares outstanding+45.3%+8.2%+1.2%−2.3%−0.4%—
Returns & profitability
Return on equity (ROE)−34.0%−138.7%−74.5%−52.8%−92.0%—
Return on invested capital (ROIC)−521.3%—————
Return on assets (ROA)−25.8%−94.7%−64.9%−48.1%−61.5%−95.4%
Return on tangible assets−19.0%−131.2%−86.7%−63.0%−36.6%−95.4%
Free cash flow margin−109.1%−672.2%————
Financial health
Total debt$2.5M$1.3M$2.2M$3.7M——
Cash & short-term investments$226.7M$69.3M$200.6M$372.0M$591.4M$115.0M
Net debt−$224.2M−$68.0M−$198.5M−$368.3M−$591.4M−$115.0M
Debt / equity0.010.020.010.01——
Debt / assets0.010.010.010.01——
Current ratio7.241.624.4715.069.948.98
Quick ratio6.501.214.5015.079.948.98
Interest coverage———-5.8-15.1—
Working capital$213.3M$38.7M$174.6M$351.9M$554.7M$104.3M
Invested capital$17.3M−$506,000−$21.0M−$12.3M−$33.4M−$180.2M
Tangible asset value$241.5M$67.5M$177.5M$356.0M$558.0M−$65.2M
Net current asset value$212.1M$38.7M$173.2M$349.7M$554.6M−$65.2M
Graham net-net per share$1.25$0.24$1.36$3.19$4.78−$0.61
Capital allocation
Share buybacks (net)$633,000$0$1,000$4,000$2,000$3,000
Capex / revenue0.3%0.6%————
Capex / depreciation0.070.040.303.6984.0084.00
Stock-based compensation / revenue21.8%78.0%————
R&D / revenue71.7%540.7%————
SG&A / revenue125.3%249.7%————
Efficiency
Days sales outstanding88.087.0————
Days of inventory on hand2,503.82,744.5-175.7-239.4-83,585.0—
Days payables outstanding1,178.32,075.5852.22,883.72,543,320.0—
Cash conversion cycle (days)1,413.5756.0————
Receivables turnover4.154.200.000.000.00—
Payables turnover0.310.180.430.130.00—
Inventory turnover0.150.13————
Asset turnover0.260.140.000.000.000.00
Average receivables$12.9M$6.1M$655,000$303,000$229,000—
Average payables$12.1M$9.2M$4.7M$3.6M$7.0M$8.2M
Average inventory$25.7M$12.2M−$976,000−$303,000−$229,000—
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%

Computed from IVVD's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

IVVD valuation and financial ratios

Invivyd earned a return on equity of −34.0% and a return on invested capital of −521.3% in fiscal 2025. It ended the year with $2.5 million of debt and $226.7 million in cash and short-term investments, a net cash position of $224.2 million. It returned $0.6 million to shareholders: $0 in dividends and $0.6 million in share buybacks. The share count rose 54.8% from 111.2M to 172.2M over 5 years.

See the IVVD income statement, the IVVD chart for price history, or the IVVD stock overview for the latest quote and news.

IVVD key metrics FAQ

What is Invivyd's return on equity?

Invivyd's return on equity (ROE) was −34.0% in fiscal 2025: net income of -$52.5 million on average shareholders' equity of $154.5 million.

What is Invivyd's ROIC?

Invivyd's return on invested capital was −521.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Invivyd have?

Invivyd had total debt of $2.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.

Does Invivyd buy back its shares?

Yes. Invivyd spent $0.6 million on net share repurchases in fiscal 2025 Shares outstanding changed +45.3% over the year, to 172.2M..

What is Invivyd's free cash flow yield?

Invivyd generated -$58.3 million of free cash flow in fiscal 2025, a free cash flow yield of −13.7% on its market value at year-end ($425.4 million).

What is Invivyd's current ratio?

Invivyd's current ratio was 7.24 at the end of fiscal 2025: current assets were 7.24 times current liabilities.

Biotechnology key metrics